Cargando…

Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease

BACKGROUND: Impairments of health related quality of life (HRQoL) are frequently observed in Fabry disease (FD) and are known to be related to neuropathic pain and cardiovascular events. This study aimed to explore the role of chronic kidney disease (CKD) in a large cohort of patients with FD. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Martin, Krämer, Johannes, Blohm, Elisabeth, Vergho, Dorothee, Weidemann, Frank, Breunig, Frank, Wanner, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280765/ https://www.ncbi.nlm.nih.gov/pubmed/25432518 http://dx.doi.org/10.1186/1471-2369-15-188

Ejemplares similares

Potential role of vitamin D deficiency on Fabry cardiomyopathy
por: Drechsler, Christiane, et al.
Publicado: (2013)

Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles
por: Oder, Daniel, et al.
Publicado: (2016)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
por: Krämer, Johannes, et al.
Publicado: (2015)

Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
por: Seydelmann, Nora, et al.
Publicado: (2016)

Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study
por: Üçeyler, Nurcan, et al.
Publicado: (2013)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
por: Weidemann, F, et al.
Publicado: (2013)

Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Fabry Disease – Underestimated in the Differential Diagnosis of Multiple Sclerosis?
por: Böttcher, Tobias, et al.
Publicado: (2013)

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
por: Liu, Dan, et al.
Publicado: (2018)

Value of the CHA(2)DS(2)-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
por: Liu, Dan, et al.
Publicado: (2018)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Will the FAbry STabilization indEX make its way to everyday clinical practice?
por: Cairns, Tereza, et al.
Publicado: (2018)

Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
por: Yousef, Zaheer, et al.
Publicado: (2013)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Myocardial lipid content in Fabry disease: a combined (1)H-MR spectroscopy and MR imaging study at 3 Tesla
por: Petritsch, B., et al.
Publicado: (2016)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018)

The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation
por: Schrezenmeier, Eva, et al.
Publicado: (2021)

Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden
por: Giesinger, Johannes M, et al.
Publicado: (2014)

Survey about the Quality of Life of Italian Patients with Fabry Disease
por: Polistena, Barbara, et al.
Publicado: (2021)

Life/2020—the future of kidney disease
por: Stenvinkel, Peter, et al.
Publicado: (2020)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Correction to: The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation
por: Schrezenmeier, Eva, et al.
Publicado: (2021)

Characterization of vertigo and hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2018)

Quality of life in patients with Fabry disease: a systematic review of the literature
por: Arends, Maarten, et al.
Publicado: (2015)

Translation of quality of life scale for pediatric patients with Fabry disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Underestimated incidence of kidney disease in nonrenal outpatient
por: Lu, Zeyuan, et al.
Publicado: (2017)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2017)

The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease
por: Sigurdardottir, Solrun, et al.
Publicado: (2021)

Depression, sleep disturbances, pain, disability and quality of LIFE in Brazilian Fabry disease patients
por: Rosa Neto, Nilton Salles, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ab4uvkci208l0q9c4i3kqla7sj